Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mersana Therapeutics
Biotech
GSK walks away from $100M bet on Mersana STING ADC
GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ADC.
James Waldron
Apr 29, 2026 6:16am
Day One pens $285M deal for Mersana
Nov 13, 2025 10:15am
Mersana lays off 55% of staff, narrows focus to B7-H4 ADC
May 6, 2025 9:40am
It’s a wrap for Merck KGaA and Mersana’s 2014 ADC pact
Dec 22, 2023 10:37am
GSK loses its STING as part of phase 1 cleanout
Nov 1, 2023 6:38am
Mersana's phase 1 ADC cancer trial breaks free of FDA hold
Oct 31, 2023 1:21pm
